Jim Cramer said the market is wrong to believe the growth story for Eli Lilly has ended during a recent broadcast [1].

This perspective challenges the prevailing investor sentiment regarding the pharmaceutical company and its weight-loss drug, Mounjaro. As investors rotate out of certain high-growth stocks, the debate over whether Eli Lilly has reached its peak valuation intensifies.

During the May 26, 2026 [1], segment of his "Mad Dash" program on CNBC, Cramer addressed the volatility surrounding the stock. He focused on the timing of the market's reaction, referencing events that occurred on the preceding Monday and Tuesday morning [1].

Cramer said the current market behavior is a "vicious rotation" [2]. He said the belief that the Eli Lilly story was "played out" is a misconception that ignores the fundamental strength of the company's product pipeline [2].

Throughout the segment, the host urged investors to reconsider their positions. He said the momentum behind the company's medical advancements continues to provide a foundation for growth, despite the short-term pressure from traders moving capital into other sectors [2].

By challenging the narrative that the stock's best days are behind it, Cramer positioned the current dip as a potential opportunity rather than a signal of decline [2]. He said the market often overreacts to rotation trends, potentially overlooking the long-term value of dominant pharmaceutical assets [2].

“vicious rotation”

This clash between Cramer's bullish outlook and the 'vicious rotation' of the market highlights a broader tension in the 2026 pharmaceutical sector. It reflects a struggle between fundamental value investors, who see continued growth in GLP-1 medications, and momentum traders who are shifting capital into new sectors after a period of intense concentration in weight-loss stocks.